Quantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D

Virology

Volumn 268, Issue 2, 2000, Pages 482-492

  Zhang, Yunfei ^a   Smith, Patrick M ^a   Jennings, Stephen R ^a   O'Callaghan, Dennis J ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ADOLESCENT; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUINE HERPES VIRUS; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LUNG; MEDIASTINUM LYMPH NODE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS VIRULENCE;

ANIMALIA; DNA VIRUSES; EQUIDAE; EQUINE HERPESVIRUS 1; HERPES; HERPESVIRIDAE; HERPESVIRUS 1;

EID: 0034653582     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0197     Document Type: Article

References (67)

1. Alber D. G., Greensill J., Killington R. A., Stokes A. Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2K) and BALB/c (H-2D) mice. Res. Vet. Sci. 59:1995;205-213.
2. Allen G. P., Bryans J. T. Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus type 1 infections. Prog. Vet. Microbiol. Immunol. 2:1986;78-144.
3. Allen G. P., Kydd J. K., Slater J. D., Smith K. C. Advances in understanding of the pathogenesis, epidemiology and immunological control of equine herpesvirus abortion. Wernery U., Wade J. F., Mumford J. A., Kaaden O.-R. Equine Infectious Diseases. 1999;129-146 R & W Publications, Newmarket.
4. Armstrong S. J., Dimmock N. J. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J. Virol. 66:1992;3823-3832.
5. Arvilommi H. ELISPOT for detecting antibody-secreting cells in response to infections and vaccination. APMIS. 104:1996;401-410.
6. Awan A. R., Chong Y.-C., Field H. J. The pathogenesis of equine herpesvirus type 1 in the mouse: A new model for studying host responses to the infection. J. Gen. Virol. 71:1990;1131-1140.
7. Awan A. R., Gibson J. S., Field H. J. A murine model for studying EHV-1 induced abortion. Res. Vet. Sci. 51:1991;94-99.
8. Bienenstock J. Brochus-associated lymphoid tissue. Bienenstock J. Immunology of the Lung and Upper Respiratory Tract. 1984;96-118 McGraw-Hill, New York.
9. Brown T. A., Murphy B. R., Radl J., Haaijman J. J., Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J. Clin. Microbiol. 22:1985;259-264.
10. Burki F., Rofsmanith W., Nowotny N., Pallan C., Mostl K., Lussy H. Viremia and abortions are not prevented by two commercial equine herpesvirus-1 after experimental challenge of horses. Vet. Q. 12:1990;80-86.
11. Burns J. W., Siadat-Pajouh M., Krishnaney A. A., Greenberg H. B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 272:1996;104-107.
12. Carson P. J., Schut R. L., Simpson M. L., O'Brien J., Janoff E. N. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J. Infect. Dis. 172:1995;340-345.
13. Colle C. F. III, Tarbet E. B., Grafton W. D., Jennings S. R., O'Callaghan D. J. Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain RacL. Virus Res. 43:1996;111-124.
14. Czerkinsky C., Moldoveanu Z., Mestecky J., Nilsson L.-Å., Ouchterlony O. A novel two color ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J. Immunol. Methods. 115:1988;31-37.
15. Czerkinsky C. C., Nilsson L.-Å., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods. 65:1983;109-121.
16. Ellis J. A., Bogdan J. R., Kanara E. W., Morley P. S., Haines D. M. Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses. J. Am. Vet. Med. Assoc. 206:1995;823-832.
17. Fievet N., Chougnet C., Dubois B., Deloron P. Quantification of antibody-secreting lymphocytes that react with Pf155/RESA from Plasmodium falciparum: An ELISPOT assay for field studies. Clin. Exp. Immunol. 91:1993;63-67.
18. Gilkerson J. R., Love D. N., Whalley J. M. A review of equine herpesvirus vaccine: From the traditional to the experimental. Aust. Equine Vet. 15:1997;27-32.
19. Gleeson L. J., Coggins L. Response of pregnant mares to equine herpesvirus 1 (EHV-1). Cornell Vet. 70:1980;391-400.
20. Gorse G. J., Belshe R. B., Munn N. J. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccine. J. Clin. Microbiol. 26:1988;911-918.
21. Guo P. X., Goebel S., Davis S., Perkus M. E., Languet B., Desmettre P., Allen G., Paoletti E. Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals. J. Virol. 63:1989;4189-4198.
22. Guo P. X., Goebel S., Perkus M. E., Taylor J., Norton E., Allen G., Languet B., Desmettre P., Paoletti E. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity. J. Virol. 64:1990;2399-2406.
23. Hameleers D. M., Van der Ven I., Biewenga J., Sminia T. Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens. Immunol. Cell Biol. 69:1991;119-125.
24. Hannant D., Jessett D. M., O'Neill T., Dolby C. A., Cook R. F., Mumford J. A. Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. Res. Vet. Sci. 54:1993;299-305.
25. Herrington D. A., Van de Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., Levine M. M. Studies in volunteers to evaluate candidate Shigella vaccines: Further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferrred by previous Shigella sonnei disease. Vaccine. 8:1990;353-357.
26. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A. M. Mucosal immunity: Implications for vaccine development. Immunology. 184:1992;157-179.
27. Hone D. M., Tacket C. O., Harris A. M., Kay B., Losonsky G., Levine M. M. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J. Clin. Invest. 90:1992;412-420.
28. Isolauri E., Joensuu J., Suomalainen H., Luomala M., Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobaccillus casei GG. Vaccine. 13:1995;310-312.
29. Kobayashi K., Ueno Y., Szuki H., Miura M., Nagatomi R., Ishii M., Toyota T. Anti-idiotypic antibody production in hepatitis B vaccine recipients. J. Gastroenterol. 29:1994;740-744.
30. Lamm M. E. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51:1997;311-340.
31. Love D. N., Bell C. W., Pye D., Edwards S., Hayden M., Lawrence G. L., Boyle D., Pye T., Whalley J. M. Expression of equine herpesvirus 1 glycoprotein D using a recombinant baculovirus. J. Virol. 67:1993;6820-6823.
32. Marshall J. S., Bienenstock H., Perdue M. H., Stanisz A. M., Stead R. H., Ernst P. B. Novel cellular interactions and networks involving the intestinal immune system and its microenvironment. APMIS. 97:1989;383-394.
33. Matsumura T., Kondo T., Sugita S., Damiani A. M., O'Callaghan D. J., Imagawa H. An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses. Virology. 242:1998;68-79.
34. Mazanec M., Kaetzel C. S., Lamm M. E., Fletcher D., Nedrud J. G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl. Acad. Sci. USA. 89:1992;6901-6905.
35. McGhee J., Kiyono H. The mucosal immune system. Paul W. E. Fundamental Immunology. 1999;909-945 Lippincott-Raven, Philadelphia.
36. McIntosh K., McQuillin J., Gardner P. S. Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. Infect. Immun. 23:1979;276-281.
37. Milligan G. N., Berstein D. I. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology. 206:1995;234-241.
38. Moldoveanu Z., Clements M. L., Prince S. J., Murphy B. R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 13:1995;1006-1012.
39. Mostov K. E. Transepithelial transport of immunoglobulins. Annu. Rev. Immunol. 12:1994;63-84.
40. Neubauer A., Beer M., Brandmuller C., Kaaden O.-R., Osterrieder N. Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection. Virology. 239:1997;36-45.
41. O'Callaghan D. J., Osterrieder N. Equine herpesviruses. Webster R. G., Granoff A. Encyclopedia of Virology. 1999;508-515 Academic PressHarcourt Brace, San Diego.
42. Onions D. Equine herpesviruses: New approaches to an old problem. Equine Vet. J. 23:1991;6-7.
43. Osterrieder N., Holden V. R., Brandmuller C., Neubauer A., Kaaden O. R., O'Callaghan D. J. The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture. Virology. 217:1996a;442-451.
44. Osterrieder N., Neubauer A., Brandmuller C., Kaaden O. R., O'Callaghan D. J. The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. Virology. 226:1996b;243-251.
45. Osterrieder N., Neubauer A., Fakler B., Brandmuller C., Seyboldt C., Kaaden O.-R., Baines J. D. Synthesis and processing of the equine herpesvirus 1 glycoprotein M. Virology. 232:1997;230-239.
46. Osterrieder N., Wagner R., Brandmuller C., Schmidt P., Wolf H., Kaaden O.-R. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:1995;500-510.
47. Osterrieder N., Wagner R., Pfeffer M., Kaaden O.-R. Expression of equine herpesvirus 1 glycoprotein protein gp14 in Escherichia coli and in insect cells: A comparative study on protein processing and humoral immune responses. J. Gen. Virol. 75:1994;2014-2016.
48. Packiarajah P., Walker C., Gilkerson J., Whalley J. M., Love D. N. Immune responses and protective efficacy of recombinant baculovirus-expressed glycoproteins of equine herpesvirus 1 (EHV-1) gB, gC, and gD alone or in combinations in BALB/c mice. Vet. Microbiol. 61:1998;261-278.
49. Palache A. M., Beyer W. E., Luchters G., Volker R., Sprenger M. J., Masurel N. Influenza vaccines: The effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. Vaccine. 11:1993;892-908.
50. Perdue M. L., Kemp M. C., Randall C. C., O'Callaghan D. J. Studies of the molecular anatomy of the L-M cell strain of equine herpesvirus type 1. Proteins of the nucleocapsid and intact virion. Virology. 59:1974;201-216.
51. Ruitenberg K. M., Walker C., Wellington J. E., Love D. N., Whalley J. M. DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Vaccine. 17:1999;237-244.
52. Sangster M., Smith F. S., Coleclough C., Hurwitz J. L. Human parainfluenzavirus type 1 immunization of infant mice projects from subsequent Sendai virus infection. Virology. 212:1995;13-19.
53. Schwartz D. H., Cosentino L. M., Shirai A., Conover J., Daniel S., Klinman D. M. Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. J. Acquir. Immune Defic. Syndr. 7:1994;447-453.
54. Sedgwick, J. D., and Holt, P. G.1983. A solid-phase immunoenzymatic technique for the enumeration of specific antibody secreting cells. J. Immunol. Methods57, 301-309.
55. Sjolander A., Lovgren B. K., Johansson M., Morein B. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand. J. Immunol. 43:1996;164-172.
56. Smith P. M., Zhang Y., Jennings S. R., O'Callaghan D. J. Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice. J. Virol. 72:1998;5366-5372.
57. Stokes A., Alber D. G., Cameron R. S., Marshall R. N., Allen G. P., Killington R. A. The production of a truncated form of baculovirus expressed EHV-1 glycoprotein C and its role in protection of C3H (H-2Kk) mice against virus challenge. Virus Res. 44:1996a;97-109.
58. Stokes A., Alber D. G., Greensill J., Amellal B., Carvalho R., Taylor L. A., Doel T. R., Killington R. A., Halliburton I. W., Meredith D. M. The expression of the equine herpesvirus 1 which share homology with herpes simplex virus 1 glycoproteins H and L. Virus Res. 40:1996b;91-107.
59. Stokes A., Allen G. P., Pullen L. A., Murray P. K. A hamster model of equine herpesvirus type 1 (EHV-1) infection: Passive protection by monoclonal antibodies to EHV-1 glycoproteins 13, 14 and 17/18. J. Gen. Virol. 70:1989;1173-1183.
60. Stokes A., Cameron R. S., Marshall R. N., Killington R. A. High level expression of equine herpesvirus 1 glycoproteins D and H and their role in protection against virus challenge in the C3H (H-2Kk) murine model. Virus Res. 50:1997;159-173.
61. Tewari D., Nair S. V., DeUngria M. C., Lawrence G. L., Hayden M., Love D. N., Field H. J., Whalley J. M. Immunization with glycoprotein C of equine herpesvirus type-1 is associated with accelerated virus clearance in a murine model. Arch. Virol. 140:1995;789-797.
62. Tewari D., Whalley J. M., Love D. N., Field H. J. Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model. J. Gen. Virol. 75:1994;1735-1741.
63. Wenneras C., Svennerholm A. M., Ahren C., Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect. Immun. 60:1992;2605-2611.
64. Wolcott R. M., Jennings S. R., Chervenak R. In utero exposure to ethanol affects postnatal development of T- and B-lymphocytes, but not natural killer cells. Alcohol. Clin. Exp. Res. 19:1995;170-176.
65. Wu H.-Y., Russell M. W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:1993;314-322.
66. Wu H.-Y., Nikolova E. B., Beagley K. W., Eldridgw J. H., Russell M. Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization. Infect. Immun. 65:1997;227-235.
67. Zhang Y., Smith P. M., Jennings S. R., O'Callaghan D. J. Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD. Virus Res. 56:1998;11-24.